ANFF-C is excited to announce that Haemograph has been awarded Gate 2 pre-seed funding to aid in the commercialisation of its novel blood rheometer. 

Haemograph is a Melbourne-based start-up revolutionising healthcare with their innovative portable, point-of-care, blood coagulation rheometer. The cutting-edge device measures the viscoelastic properties of blood, providing crucial clinical insights such as clot formation time, clot strength and clot structure. 

Initially, Haemograph’s rheometer will enhance blood-clotting control during and after surgery, ensuring better patient outcomes. 

Development of this state-of-the-art technology was enabled through collaboration with CSIRO and ANFF-VIC’s Melbourne Centre for Nanofabrication. 

ANFF-C uses both its financial and human resources to help ANFF-derived technologies realise their commercial potential. We support the launch of new businesses and empower them to attract capital from professional investors by decreasing the risks associated with early-stage entities. With pre-seed funding support up to $120,000, ANFF-C Director John Morrison works with recipients to determine the bespoke services that best position their IP to successfully attract investors and find the right path to market. 

ANFF and ANFF-C are proud to be enabling the continuing journey of Haemograph from conception through commercialisation. Stay tuned for more updates as they continue to push the boundaries of medical technology! 

For more information about Haemograph, visit their website at https://haemograph.com.au/ 

To learn more about ANFF-C and ANFF’s support for commercialisation, visit https://anff.org.au/commercialisation/